ALERT: This system is being upgraded on Tuesday December 12. It will not be available for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace will be disabled on Monday December 11, so no new items are to be added to the repository while the upgrade is in progress. Everything should be back to normal by the end of day, December 12.

Show simple item record

Synthetic nicotine has arrived Jordt, Sven-Eric 2021-09-08T17:17:39Z 2021-09-08T17:17:39Z
dc.identifier.issn 0964-4563
dc.identifier.issn 1468-3318
dc.description.abstract <jats:p>The introduction of a new product line of the popular disposable electronic cigarette brand Puffbar, advertised as containing synthetic nicotine, has drawn attention to the increasing use of synthetic nicotine in marketed products and its uncertain regulatory status. A search of the Truth Tobacco Industry Documents revealed that the industry considered using synthetic nicotine already in the 1960s, efforts that were abandoned due to high costs and insufficient purity. Recent patents revealed renewed efforts to develop more efficient strategies for the synthesis of nicotine. Nicotine exists as two stereoisomers, <jats:italic>S</jats:italic>-nicotine and <jats:italic>R</jats:italic>-nicotine. While <jats:italic>S</jats:italic>-nicotine is the prevalent (&gt;99%) form of nicotine in tobacco, a market-leading form of synthetic nicotine contains both stereoisomers at equal amounts, raising concerns about inaccurate labelling and the poorly understood health effects of <jats:italic>R</jats:italic>-nicotine. Other manufacturers, including a leading vendor of pharmaceutical grade nicotine, developed stereospecific strategies to synthesise pure <jats:italic>S</jats:italic>-nicotine, now added to electronic cigarette products marketed in the USA and UK. While <jats:italic>S</jats:italic>-nicotine and <jats:italic>R</jats:italic>-nicotine can be differentiated by enantioselective High Performance Liquid Chromatography (HPLC), differentiation of synthetic (fossil-derived) from tobacco-derived <jats:italic>S</jats:italic>-nicotine will require development of methods to measure carbon isotope (<jats:sup>14</jats:sup>C or <jats:sup>13</jats:sup>C) content. Vendors claim that the FDA has no authority to regulate synthetic nicotine as a tobacco product, allowing them to circumvent the premarket tobacco product application process. However, legal analysis suggests that FDA may have the authority to regulate synthetic nicotine as a drug. Alternatively, Congress needs to include nicotine from any source within the legal definition of tobacco products.</jats:p>
dc.language en
dc.publisher BMJ
dc.relation.ispartof Tobacco Control
dc.relation.isversionof 10.1136/tobaccocontrol-2021-056626
dc.title Synthetic nicotine has arrived
dc.type Journal article Jordt, Sven-Eric|0637952 2021-09-08T17:17:38Z
pubs.organisational-group School of Medicine
pubs.organisational-group Pharmacology & Cancer Biology
pubs.organisational-group Anesthesiology
pubs.organisational-group Duke
pubs.organisational-group Basic Science Departments
pubs.organisational-group Clinical Science Departments
pubs.publication-status Published online

Files in this item


This item appears in the following Collection(s)

Show simple item record